MorphoSys (MOR) Competitors $18.96 0.00 (0.00%) As of 06/30/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MOR vs. ASND, VTRS, QGEN, MRNA, BPMC, VRNA, BBIO, ROIV, RVMD, and ELANShould you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. MorphoSys vs. Its Competitors Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines Verona Pharma PLC American Depositary Share BridgeBio Pharma Roivant Sciences Revolution Medicines Elanco Animal Health MorphoSys (NASDAQ:MOR) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk. Which has preferable earnings & valuation, MOR or ASND? MorphoSys has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45Ascendis Pharma A/S$393.54M26.89-$409.12M-$6.28-27.56 Do analysts rate MOR or ASND? Ascendis Pharma A/S has a consensus price target of $220.67, suggesting a potential upside of 27.48%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Ascendis Pharma A/S 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, MOR or ASND? MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Does the media favor MOR or ASND? In the previous week, Ascendis Pharma A/S had 5 more articles in the media than MorphoSys. MarketBeat recorded 5 mentions for Ascendis Pharma A/S and 0 mentions for MorphoSys. Ascendis Pharma A/S's average media sentiment score of 1.20 beat MorphoSys' score of 0.00 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Overall Sentiment MorphoSys Neutral Ascendis Pharma A/S Positive Is MOR or ASND more profitable? Ascendis Pharma A/S has a net margin of -93.22% compared to MorphoSys' net margin of -226.79%. Ascendis Pharma A/S's return on equity of 0.00% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% Ascendis Pharma A/S -93.22%N/A -33.29% Do insiders & institutionals have more ownership in MOR or ASND? 18.4% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryAscendis Pharma A/S beats MorphoSys on 10 of the 16 factors compared between the two stocks. Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOR vs. The Competition Export to ExcelMetricMorphoSysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.86B$782.11M$5.54B$8.87BDividend YieldN/A4.84%5.39%4.10%P/E Ratio-5.451.0926.2319.90Price / Sales11.99219.25413.23113.66Price / CashN/A23.4436.1356.90Price / Book54.175.998.045.38Net Income-$205.35M-$27.64M$3.15B$248.50M7 Day PerformanceN/A-0.07%1.44%2.04%1 Month PerformanceN/A6.49%3.62%4.84%1 Year Performance4.18%8.20%34.68%20.23% MorphoSys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730ASNDAscendis Pharma A/S3.5796 of 5 stars$175.78-0.6%$220.67+25.5%+27.0%$10.81B$393.54M-27.991,017Positive NewsVTRSViatris3.0627 of 5 stars$8.85-0.2%$10.40+17.5%-10.5%$10.41B$14.33B-2.7932,000QGENQiagen3.7836 of 5 stars$46.72-0.1%$47.74+2.2%+22.8%$10.39B$1.98B117.145,765Dividend AnnouncementMRNAModerna4.3699 of 5 stars$25.67-0.9%$46.61+81.6%-74.1%$10.02B$3.24B-2.945,800Trending NewsOptions VolumeBPMCBlueprint Medicines1.5574 of 5 stars$128.40+0.2%$128.06-0.3%+16.2%$8.28B$508.82M-51.98640High Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.5901 of 5 stars$97.05+2.9%$101.10+4.2%+482.7%$8.03B$42.28M-48.5330Positive NewsAnalyst ForecastBBIOBridgeBio Pharma4.7146 of 5 stars$42.17+1.1%$56.67+34.4%+71.9%$7.92B$221.90M-11.95400Analyst ForecastInsider TradeROIVRoivant Sciences1.9443 of 5 stars$11.50+0.4%$17.50+52.2%+3.9%$7.78B$29.05M-46.00860RVMDRevolution Medicines4.4993 of 5 stars$40.04+1.0%$67.08+67.5%-0.5%$7.39B$11.58M-10.01250Analyst RevisionGap UpELANElanco Animal Health2.3429 of 5 stars$13.36-0.7%$15.17+13.5%+5.1%$6.68B$4.44B18.059,000Analyst Forecast Related Companies and Tools Related Companies ASND Competitors VTRS Competitors QGEN Competitors MRNA Competitors BPMC Competitors VRNA Competitors BBIO Competitors ROIV Competitors RVMD Competitors ELAN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MOR) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MOR Stock Alerts